Associated equity: InMed Pharmaceuticals
Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
InMed Pharmaceuticals — 14 videos in collection
InMed Pharmaceuticals (INM) is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol, and is developing IntegraSyn to produce pharmaceutical-grade cannabinoids. InMed recently announced that it has entered into a definitive agreement to acquire BayMedica, a revenue-stage biotechnology company leveraging synthetic biology and pharmaceutical chemistry to develop an efficient, scalable and proprietary platform to produce high-quality, rare cannabinoids for consumer applications. The combined company will be a market leader in the manufacture of rare cannabinoids.
In this webinar, InMed chief executive officer Eric Adams and BayMedica chief executive officer Dr Shane Johnson discuss the acquisition and their plans for the newly combined company.